https://www.selleckchem.com/pr....oducts/monomethyl-au
Total RQLQ scores indicated significant improvement (P .0001) in quality of life. Over 77% of participants achieved the MCID (≥0.5 points) for the total RQLQ score. According to the CGI-I, ≥83.0% experienced improvement at all but the 12-month visit (61.9%). One participant experienced two treatment-related serious adverse events (epistaxis and retained pledget). A total of 29 nonserious treatment-related AEs were reported in 23 participants; most events were transient and resolved with little to no interventio
Curtir
Comentario
Compartilhar
